Oxymorphone: a review

@article{Prommer2005OxymorphoneAR,
  title={Oxymorphone: a review},
  author={Eric Prommer},
  journal={Supportive Care in Cancer},
  year={2005},
  volume={14},
  pages={109-115}
}
  • E. Prommer
  • Published 1 February 2006
  • Medicine
  • Supportive Care in Cancer
Oxymorphone (oxymorphone hydrochloride) (14-hydroxy-dihydromorphinone), a semisynthetic μ-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy… 

Oral extended-release oxymorphone: a new choice for chronic pain relief

Oxymorphone ER is the only long-acting opioid that contains oxymorphone, which exhibits some distinct pharmacologic properties compared with most other opioids, including a longer half-life, higher affinity for the µ-opioid receptor, and lack of interaction with the CYPP450 drug-metabolizing system.

Ketorolac, Oxymorphone, Tapentadol, and Tramadol: A Comprehensive Review.

Single- and Multiple-Dose Pharmacokinetic and Dose-Proportionality Study of Oxymorphone Immediate-Release Tablets

This study examined the pharmacokinetics and dose proportionality of a new immediate-release (IR) tablet formulation of oxymorphone and its metabolites following single- and multiple-dose administration in healthy volunteers and found that opioid formulations provide predictable increases in drug concentration with increasing dose.

Chemistry and synthesis of major opium alkaloids: a comprehensive review

Among analgesic drugs, the opioid class of compounds still remains one of the most important medicines for severe and chronic pain treatment. Hence, developing novel and effective synthetic method of

Role of active metabolites in the use of opioids

Clinicians need to be aware that many opioids have active metabolites that will become therapeutically important, for example in cases of altered pathology, drug interactions and genetic polymorphisms of drug-metabolizing enzymes.

Pharmacokinetics of oxymorphone in cats.

The disposition of oxymorphone in cats is characterized by a moderate volume of distribution and a short terminal half-life, both of which are characteristic of spayed female cats.

Pharmacokinetic and Pharmacodynamic Modeling of Opioid-Induced Gastrointestinal Side Effects in Patients Receiving Tapentadol IR and Oxycodone IR

Simulations show that AE incidence following administration of tapentadol IR is lower than that following oxycodone IR intake within the investigated range of analgesic noninferiority dose ratios, consistent with reported in vitro receptor binding affinities for these compounds.

Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

Drug interactions arising from CYP2D6 inhibition most likely have minor clinical importance for oral oxycodone if the function of the CYP3A4 pathway is normal.

Cancer Pain Management: Opioid Analgesics, Part 2

  • R. Wickham
  • Medicine, Biology
    Journal of the advanced practitioner in oncology
  • 2017
Clinicians must understand the metabolism, pharmacokinetics, and elimination of particular drugs to individualize opioid selection, select initial doses, and appropriately escalate doses to satisfactory pain relief or uncontrollable toxicity.
...

References

SHOWING 1-10 OF 32 REFERENCES

Single- and Multiple-Dose Pharmacokinetic and Dose-Proportionality Study of Oxymorphone Immediate-Release Tablets

This study examined the pharmacokinetics and dose proportionality of a new immediate-release (IR) tablet formulation of oxymorphone and its metabolites following single- and multiple-dose administration in healthy volunteers and found that opioid formulations provide predictable increases in drug concentration with increasing dose.

Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I.

Pharmacokinetic drug-drug interactions with morphine, hydromorphone, and oxymorphone are reviewed in this column and suggest that inhibition or induction of UGT enzymes could alter morphine and its metabolite levels.

Comparisons of the Analgesic Effects of Oral and Intramuscular Oxymorphone and of Intramuscular Oxymorphone and Morphine in Patients with Cancer

The relative analgesic potency of oral and intramuscular oxymorphone was evaluated in a double-blind crossover comparison of graded single doses in patients with chronic pain due to cancer and the occurrence of side effects was qualitatively and quantitatively similar.

Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study

Cancer patients stabilized on morphine CR or oxycodone CR were safely and rapidly converted to a lower milligram dose of oxymorphone ER that provided adequate pain relief with comparable tolerability, and these results justify additional trials with oxymorphones ER.

A comparison of morphine, meperidine, and oxymorphone as utilized in patient-controlled analgesia following cesarean delivery.

Whereas morphine is a more commonly utilized PCA analgesic, the excellent analgesia, low incidence of sedation, and high patient satisfaction provided by meperidine and oxymorphone suggested useful alternatives.

Sublingual absorption of selected opioid analgesics

The results indicate that although the sublingual absorption and apparent sublingUAL bioavailability of morphine are poor, the sublingsual absorption of methadone, fentanyl, and buprenorphine under controlled conditions is relatively high.

The Efficacy and Safety of Oral Immediate-Release Oxymorphone for Postsurgical Pain

Oxymorphone IR 10, 20, or 30 mg provided significant dose-related pain relief compared with placebo, and this relief was maintained over several days with a safety profile comparable to that of oxycodone IR.

Identification of Opioid Ligands Possessing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone

Results indicate that appropriate molecular manipulations of the morphinan templates could provide ligands with mixed micro agonist/delta antagonist profiles and such ligands may have the potential of emerging as novel analgesic drugs devoid of tolerance, dependence, and related side effects.

Pharmacokinetics and Dose‐Proportionality of Oxymorphone Extended Release and Its Metabolites: Results of a Randomized Crossover Study

Evaluating the pharmacokinetics and dose‐proportionality of four dose strengths of oxymorphone extended release under both single‐dose and steady‐state conditions finds no significant differences between the strengths.